Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.76 |
| ▸ | AANAT | Q16613 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 6/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | MMP9 | P14780 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31114206 | 1.00 | MTNR1A (0.76) | MTNR1AAANATMEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL3826492 | 0.99 | MTNR1A (0.74) | MTNR1AAANATMEN1KMT2ALMNA | |
| SCHEMBL761481 | 0.90 | MTNR1A (0.88) | MTNR1AAANATMEN1KMT2ALMNA | |
| SCHEMBL7677886 | 0.87 | MEN1 (0.84) | MTNR1AAANATMEN1KMT2ALMNA | |
| SCHEMBL5903804 | 0.87 | AANAT (0.77) | MTNR1AAANATMEN1KMT2ALMNA | |
| SCHEMBL10069200 | 0.87 | AANAT (0.77) | MTNR1AAANATMEN1KMT2ALMNA | |
| SCHEMBL1068274 | 0.87 | MTNR1A (1.00) | MTNR1AAANATMEN1KMT2ALMNA | |
| SCHEMBL20227977 | 0.86 | AANAT (0.75) | MTNR1AAANATMEN1KMT2ALMNA | |
| SCHEMBL6424908 | 0.86 | AANAT (1.00) | MTNR1AAANATMEN1KMT2ALMNA | |
| SCHEMBL6424904 | 0.86 | AANAT (0.75) | MTNR1AAANATMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099815-A2 | NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS | Acure Pharma AB (SE) | 2009-09-16 | — | — | EP | claimed |
| WO-2008058679-A2 | NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS | ACURE PHARMA AB (SE) | 2008-05-22 | — | — | WO | claimed |
| US-20260138947-A1 | BENZYLTRYPTAMINE COMPOUNDS | REUNION NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260042735-A1 | BENZYLTRYPTAMINE COMPOUNDS | REUNION NEUROSCIENCE INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20240400510-A1 | NOVEL BENZYLTRYPTAMINE COMPOUNDS | REUNION NEUROSCIENCE INC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4423061-A1 | NOVEL BENZYLTRYPTAMINE COMPOUNDS | Reunion Neuroscience, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023125751-A1 | DIA-BASED QUANTITATIVE CHEMICAL PROTEOMICS TARGET SCREENING METHOD | 北京大学 | 2023-07-06 | — | — | WO | disclosed |
| US-20230144974-A1 | BENZYLTRYPTAMINE COMPOUNDS | REUNION NEUROSCIENCE INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023070228-A1 | NOVEL BENZYLTRYPTAMINE COMPOUNDS | REUNION NEUROSCIENCE CANADA INC. (CA) | 2023-05-04 | — | — | WO | disclosed |
| US-10889556-B2 | Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190106398-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-11 | — | — | US | disclosed |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| US-8138218-B2 | Growth hormone secretagogues | IPSEN PHARMA S.A.S. (FR) | 2012-03-20 | — | — | US | disclosed |
| EP-2099815-A2 | NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS | Acure Pharma AB (SE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090131478-A1 | Growth Hormone Secretagogues | IPSEN PHARMA S.A.S. (FR) | 2009-05-21 | — | — | US | disclosed |
| WO-2008058679-A2 | NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS | ACURE PHARMA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| EP-1254114-A2 | MELANOCORTIN RECEPTOR AGONISTS AND ANTAGONISTS | Melacure Therapeutics AB (SE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055106-A2 | NOVEL MELANOCORTIN RECEPTOR AGONISTS AND ANTAGONISTS | MELACURE THERAPEUTICS AB (SE) | 2001-08-02 | — | — | WO | disclosed |
| WO-1995025514-A1 | COMPOUNDS USEFUL AS ANXIOLYTIC, SEDATIVE, AND HYPNOTIC AGENTS | DISCOVERY THERAPEUTICS, INC. (US) | 1995-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106398-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE | POLRMT, RNASE1, POLM | MTNR1A 2103/4885AANAT 682/4885MEN1 3312/4885 |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | HDGF, HCCS, CCNC | MTNR1A 570/4885AANAT 1969/4885MEN1 86/4885 |
| US-20240400510-A1 | NOVEL BENZYLTRYPTAMINE COMPOUNDS | HTR2C, HTR2A, HTR3B | MTNR1A 159/4885AANAT 209/4885MEN1 1581/4885 |
| US-20260042735-A1 | BENZYLTRYPTAMINE COMPOUNDS | HTR2C, HTR2A, HTR6 | MTNR1A 278/4885AANAT 347/4885MEN1 2882/4885 |
| US-20230144974-A1 | BENZYLTRYPTAMINE COMPOUNDS | HTR2C, HTR2A, HTR3B | MTNR1A 166/4885AANAT 265/4885MEN1 1121/4885 |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | MTNR1A 683/4885AANAT 309/4885MEN1 3832/4885 |
| US-20090131478-A1 | Growth Hormone Secretagogues | GHSR, GHRHR, GHITM | MTNR1A 478/4885AANAT 1746/4885MEN1 234/4885 |
| US-20260138947-A1 | BENZYLTRYPTAMINE COMPOUNDS | HTR2C, CNR2, HTR3B | MTNR1A 281/4885AANAT 451/4885MEN1 2816/4885 |
| US-10889556-B2 | Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease | POLRMT, RNASE1, POLM | MTNR1A 2103/4885AANAT 682/4885MEN1 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.